917 results on '"Biller, Beverly"'
Search Results
2. Levoketoconazole treatment in endogenous Cushings syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes.
3. Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
4. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
5. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
6. Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
7. Consensus on diagnosis and management of Cushing's disease: a guideline update
8. Improvements in diabetes and hypertension were sustained over long-term osilodrostat treatment in patients with Cushing's disease: A pooled analysis of LINC 3 and LINC 4
9. Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
10. Current concepts of the diagnosis of adult growth hormone deficiency
11. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
12. Growth hormone replacement in adults: Real-world data from two large studies in US and Europe
13. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
14. A Pituitary Society update to acromegaly management guidelines
15. Multidisciplinary management of acromegaly: A consensus
16. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
17. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care
18. Medical Management of Cushing Disease
19. Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
20. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
21. THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
22. THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
23. Medical Therapies in Cushing’s Syndrome
24. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
25. Biochemical Control During Long-Term Follow-Up of 230 Adult Patients with Cushing Disease: A Multicenter Retrospective Study
26. Radiation Therapy in Patients With Cushing Disease
27. In the Phase III studies LINC 3 and LINC 4, osilodrostat was effective and well tolerated in patients of Asian and non-Asian origin with Cushing's disease
28. Pooled analysis from two osilodrostat Phase III studies in Cushing's disease (LINC 3 and LINC 4): Clinical improvements according to urinary and late-night salivary cortisol levels
29. Pooled analysis of osilodrostat dosing across LINC 2, LINC 3 and LINC 4 in Cushing's disease
30. Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data from NordiNet® IOS and ANSWER
31. Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
32. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
33. Complications of Cushing's syndrome: state of the art
34. Cyclic Cushing’s Disease
35. Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
36. Status of long-acting-growth hormone preparations — 2015
37. Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
38. Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
39. Supplementary Material for 'Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data from NordiNet® IOS and ANSWER'
40. Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly
41. Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary clinicians
42. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly
43. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
44. PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
45. PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
46. PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
47. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension
48. Outcomes of Proton Therapy for Patients With Functional Pituitary Adenomas
49. The current state of long-acting growth hormone preparations for growth hormone therapy
50. Medical Therapies in Cushing’s Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.